TrialEye (London, England)2024

Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration (nAMD): phase 2 trials in treatment-naïve and anti-VEGF pretreated patients.

Daniel S Pereira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.